Implications of controlled short-wavelength light exposure for sleep in older adults

Mariana G Figueiro, Natalia Z Lesniak, Mark S Rea, Mariana G Figueiro, Natalia Z Lesniak, Mark S Rea

Abstract

Background: Environmental and physiological conditions make older adults more likely to lose synchronization to their local time and experience sleep disturbances. A regular, 24-hour light/dark cycle promotes synchronization. It is now well established that the circadian system is maximally sensitive to short-wavelength (blue) light. The purpose of the present study was to measure dose effectiveness (amounts and durations) of short-wavelength (blue) light for stimulating the circadian systems of older adults. We investigated the impact of six corneal irradiances (0.7 to 72 μW/cm2) of 470-nm light on nocturnal melatonin production. Nine participants, each over 50 years of age completed a within-subjects study. Each week, participants were exposed to one of the six irradiances of 470-nm light for 90 minutes.

Findings: A two-factor (6 corneal irradiances × 10 exposure durations), within-subjects analysis of variance (ANOVA) was conducted using the melatonin suppression levels. The ANOVA revealed a significant main effect of corneal irradiance (F5, 30 = 9.131, p < 0.0001), a significant main effect of exposure duration (F9, 54 = 5.731, p < 0.0001), and a significant interaction between these two variables (F45,270 = 1.927, p < 0.001). Post hoc t-tests revealed that corneal irradiances as low as 2 μW/cm2 reliably suppressed melatonin after 90-minute exposure whereas 0.7 μW/cm2 did not.

Conclusions: Sleep disorders are common and a serious problem for millions of older adults. The present results showed that comfortable, precise and effective doses of light can be prescribed to older adults to reliably stimulate the circadian system that presumably would promote entrainment and, thus, regular sleep. Field studies on the impact of short-wavelength-light doses on sleep efficiency in older adults should be performed.

Figures

Figure 1
Figure 1
Melatonin suppression for saliva and plasma samples.
Figure 2
Figure 2
Estimation of threshold dose at different exposure durations using the difference between melatonin concentrations in the dark and at 0.7 μW/cm2 as well as the difference between melatonin concentrations in the dark and at 2 μW/cm2. The asterisk indicates a statistically reliable difference at p = 0.05.

References

    1. Rea MS, Figueiro MG, Bullough JD. Circadian photobiology: An emerging framework for lighting practice and research. Light Res Technol. 2002;34:177–190. doi: 10.1191/1365782802lt057oa.
    1. Van Someren EJ. Circadian rhythms and sleep in human aging. Chronobiol Int. 2000;17:233–243. doi: 10.1081/CBI-100101046.
    1. Weale R. The Senescence of Human Vision. Oxford: University Press; 1992.
    1. Ancoli-Israel S, Kripke DF. Prevalent sleep problems in the aged. Biofeedback Self Regul. 1991;16:349–359. doi: 10.1007/BF00999989.
    1. Pollak CP, Perlick D. Sleep problems and institutionalization of the elderly. J Geriatr Psychiatry Neurol. 1991;4:204–210. doi: 10.1177/089198879100400405.
    1. Van Someren EJ, Hagebeuk E, Lijzenga C, Scheltens P, de Rooij S, Jonker C. et al.Circadian rest-activity rhythm disturbances in Alzheimer's disease. Biol Psychiatry. 1996;40:259–270. doi: 10.1016/0006-3223(95)00370-3.
    1. Ancoli-Israel S, Gehrman P, Martin JL, Shochat T, Marler M, Corey-Bloom J. et al.Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patients. Behav Sleep Med. 2003;1:22–36. doi: 10.1207/S15402010BSM0101_4.
    1. Van Someren EJ, Kessler A, Mirmirann M, Swaab D. Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. Biol Psychiatry. 1997;41:955–963. doi: 10.1016/S0006-3223(97)89928-3.
    1. Mishima K, Hishikawa Y, Okawa M. Randomized, dim light controlled, crossover test of morning bright light therapy for rest-activity rhythm disorders in patients with vascular dementia and dementia of Alzheimer's type. Chronobiol Int. 1998;15:647–654. doi: 10.3109/07420529808993200.
    1. Mishima K, Okawa M, Hishikawa Y, Hozumi S, Hori H, Takahashi K. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand. 1994;87:1–7.
    1. Koyama E, Matsubara H, Nakano T. Bright light treatment for sleep-wake disturbances in aged individuals with dementia. Psychiatry Clin Neurosci. 1999;53:227–229. doi: 10.1046/j.1440-1819.1999.00483.x.
    1. Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. Jama. 2008;299:2642–2655. doi: 10.1001/jama.299.22.2642.
    1. Campbell SS, Terman M, Lewy AJ, Dijk DJ, Eastman CI, Boulos Z. Light treatment for sleep disorders: consensus report. V. Age-related disturbances. J Biol Rhythms. 1995;10:151–154. doi: 10.1177/074873049501000207.
    1. Dowling GA, Burr RL, Van Someren EJ, Hubbard EM, Luxenberg JS, Mastick J. et al.Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc. 2008;56:239–246. doi: 10.1111/j.1532-5415.2007.01543.x.
    1. Dowling GA, Hubbard EM, Mastick J, Luxenberg JS, Burr RL, Van Someren EJ. Effect of morning bright light treatment for rest-activity disruption in institutionalized patients with severe Alzheimer's disease. Int Psychogeriatr. 2005;17:221–236. doi: 10.1017/S1041610205001584.
    1. Brainard G, Hanifin J, Greeson J, Byrne B, Glickman G, Gerner E. et al.Action spectrum for melatonin regulation in humans: Evidence for a novel circadian photoreceptor. J Neurosci. 2001;21:6405–6412.
    1. Rea MS, Figueiro MG, Bullough JD, Bierman A. A model of phototransduction by the human circadian system. Brain Res Rev. 2005;50:213–228. doi: 10.1016/j.brainresrev.2005.07.002.
    1. Thapan K, Arendt J, Skene DJ. An action spectrum for melatonin suppression: evidence for a novel non-rod, non-cone photoreceptor system in humans. J Physiol. 2001;535:261–267. doi: 10.1111/j.1469-7793.2001.t01-1-00261.x.
    1. Figueiro MG, Bierman A, Bullough JD, Rea MS. A personal light-treatment device for possibly improving sleep quality in the elderly: Dynamics of nocturnal melatonin suppression at two exposure levels. Chronobiology International. 2009;26:726–739. doi: 10.1080/07420520902927809.
    1. Roenneberg T, Wirz-Justice A, Merrow M. Life between clocks: daily temporal patterns of human chronotypes. J Biol Rhythms. 2003;18:80–90. doi: 10.1177/0748730402239679.
    1. Zeitzer J, Dijk D, Kronauer R, Brown E, Czeisler C. Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol. 2000;526(Pt 3):695–702.
    1. Luckiesh MH, Guth SK. Brightnesses in visual field at borderline between comfort and discomfort (BCD) Illuminating Engineering. 1949. pp. 650–670.
    1. Bullough JD. The blue-light hazard: A review. Journal of the Illuminating Engineering Society. 2000;29:6–14, 141.
    1. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB. et al.Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18:425–432.
    1. McCurry SM, Ancoli-Israel S. Sleep Dysfunction in Alzheimer's Disease and Other Dementias. Curr Treat Options Neurol. 2003;5:261–272. doi: 10.1007/s11940-003-0017-9.
    1. Van Someren EJ. Circadian and sleep disturbances in the elderly. Exp Gerontol. 2000;35:1229–1237. doi: 10.1016/S0531-5565(00)00191-1.
    1. Figueiro MG, Rea MS, LEDs. Proceedings of the CIE Midterm Meeting and International Lighting Congress 12-21 May, 2005. Leon, Spain. Commission Internationale de L'Eclairage; 2005. Improving the sleep quality of older adults.
    1. Figueiro MG, Saldo E, Rea MS, Kubarek K, Cunningham J. et al.Developing Architectural Lighting Designs to Improve Sleep in Older Adults. The Open Sleep Journal. 2008;12:40–51.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere